CRNX vs INVA
CRNX: A commercial-stage endocrine pharmaceutical company with a first-in-class oral GPCR-targeted therapy for acromegaly and a deep pipeline of programs across multiple endocrine diseases. INVA: A diversified biopharmaceutical company combining respiratory royalties from GSK blockbusters (BREO, ANORO) with a growing critical care and infectious disease platform (GIAPREZA, XACDURO, ZEVTERA, NUZOLVENCE).
Side-by-side fundamentals
| Metric | CRNX | INVA | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $83.63 | $21.30 | |
| Market cap as of 2026-07-31 | $8.9B | $1.6B | |
| P/E as of 2026-07-31 | n/a | 3.12 | |
| PEG as of 2026-07-31 | -0.47 | n/a | |
| Net margin as of 2026-07-31 | -2747.2% | +119.9% | INVA higher |
| Gross margin as of 2026-07-31 | +86.0% | +73.7% | CRNX higher |
| Operating margin as of 2026-07-31 | -3020.3% | +38.1% | INVA higher |
| ROE as of 2026-07-31 | -44.0% | +47.6% | INVA higher |
| ROA as of 2026-07-31 | -39.6% | +32.4% | INVA higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.19 | CRNX lower |
| Revenue growth (YoY) as of 2026-07-31 | +2277.5% | +13.8% | CRNX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +7.5% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-07-31 | 1.10 | 0.35 | |
| 1-year return as of 2026-07-30 close | +186.1% | +13.8% | CRNX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.